tocilizumab,obinutuzumab,glofitamab
jw pharma,roche
['glofitamab', 'np30179', 'cml']
#17icml np30179 phase ii expansion study of glofitamab. almost 50% primary refractory. cr40% median fu 16.2 m ongoing crs 68%. 
Happily married. Hematologist & SC Transplanter. field of interest: lymphoma-myeloma &chemoresistance biomarkers. @HematoClinicBCN @hematosantpau.@GELL01433166